Literature DB >> 15297076

The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials.

Stephen Conaty1, Lorna Watson, Jacqueline Dinnes, Norman Waugh.   

Abstract

The use of pneumococcal polysaccharide vaccine has remained controversial since licensure, especially in the elderly. Observational studies form much of the evidence base. We conducted a systematic review of observational studies and compared results with those obtained from an earlier review of randomised controlled trials (RCTs). Estimates of protection against invasive disease from observational studies were consistent, homogenous and compatible with sparse information obtained from RCTs. Studies were of moderate quality. From 13 observational studies the estimate of vaccine efficacy against invasive disease was 53% (46-59%) compared with 38% (-4 to 63%) from nine RCTs. Estimates of protection against all-cause pneumonia were based on fewer, heterogeneous studies that were not consistent with the findings from RCTs for this outcome. From five studies combined efficacy was 32% (7-50%) compared with 3% (-16 to 19%) from 13 RCTs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15297076     DOI: 10.1016/j.vaccine.2003.08.050

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  33 in total

1.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

2.  Polysaccharide pneumococcal vaccination: new evidence.

Authors:  A J Hall
Journal:  Thorax       Date:  2006-03       Impact factor: 9.139

3.  Pneumococcal vaccination in general internal medicine practice: current practice and future possibilities.

Authors:  Allison Kempe; Laura Hurley; Shannon Stokley; Matthew F Daley; Lori A Crane; Brenda L Beaty; L Miriam Dickinson; Christine Babbel; Jennifer Barrow; John F Steiner
Journal:  J Gen Intern Med       Date:  2008-10-02       Impact factor: 5.128

4.  Identification of new risk factors for pneumonia: population-based case-control study.

Authors:  Yana Vinogradova; Julia Hippisley-Cox; Carol Coupland
Journal:  Br J Gen Pract       Date:  2009-10       Impact factor: 5.386

5.  Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São Paulo State, Brazil.

Authors:  Joao Tonolio Neto; Gabriela Tannus Branco de Araujo; Anna Gagliardi; Amanda Pinho; Laure Durand; Marcelo Fonseca
Journal:  Hum Vaccin       Date:  2011-10-01

6.  Discrepant serological assays for Pneumococcus in renal transplant recipients - a prospective study.

Authors:  Jay A Fishman; David N Iklé; Robert A Wilkinson
Journal:  Transpl Int       Date:  2017-05-02       Impact factor: 3.782

7.  Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland.

Authors:  Pawel Grzesiowski; Raquel Aguiar-Ibáñez; Aleksandra Kobryń; Laure Durand; Pierre-Emmanuel Puig
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

Review 8.  Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice.

Authors:  Angel Vila-Corcoles; Olga Ochoa-Gondar
Journal:  Drugs Aging       Date:  2013-05       Impact factor: 3.923

9.  Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older.

Authors:  Angel Vila-Corcoles; Olga Ochoa-Gondar; Jorge A Guzmán; Teresa Rodriguez-Blanco; Elisabet Salsench; Cruz M Fuentes
Journal:  BMC Infect Dis       Date:  2010-03-18       Impact factor: 3.090

Review 10.  Vaccines for preventing pneumococcal infection in adults.

Authors:  Sarah Moberley; John Holden; David Paul Tatham; Ross M Andrews
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.